Who Paid My Doc
Maurice Brownlee
Nurse Practitioner, Psychiatric/Mental Health Chicago, IL Nurse Practitioner
NPI 1083145262 CMS profile 10952680
1823 W 47Th St, Chicago, IL 60609
General payments
$151,358
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$10,600
Through program year 2025, Maurice Brownlee of Chicago, IL is reported in the CMS Open Payments database as having received $151,358 across 1,122 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,600 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $40,762 | 270 | |
| 2024 | General | $64,894 | 347 | |
| 2023 | General | $31,602 | 285 | |
| 2022 | General | $10,884 | 172 | |
| 2021 | General | $3,214 | 48 |
Beside peers
- Maurice Brownlee
- Nurse Practitioner, Psychiatric/Mental Health median
- Middle half of Nurse Practitioner, Psychiatric/Mental Health
- National median
In program year 2025, general payments to Maurice Brownlee were reported at $40,762. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.
Show as a table
| Year | Maurice Brownlee | Nurse Practitioner, Psychiatric/Mental Health median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $3,214 | $166 | $54–$482 | $132 |
| 2022 | $10,884 | $195 | $66–$559 | $149 |
| 2023 | $31,602 | $233 | $82–$673 | $160 |
| 2024 | $64,894 | $236 | $84–$688 | $164 |
| 2025 | $40,762 | $258 | $93–$764 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 99 drugsPart D claims
3,273
Drug cost
$3,400,514
Branded share of claims
54.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 167 | $726,536 | |
| Serostim Somatropin | Brand | 22 | $537,901 | |
| Cabenuva Cabotegravir/Rilpivirine | Brand | 61 | $398,586 | |
| Mounjaro Tirzepatide | Brand | 366 | $380,867 | |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | Brand | 30 | $236,669 | |
| Ozempic Semaglutide | Brand | 132 | $123,169 | |
| Tivicay Dolutegravir Sodium | Brand | 38 | $114,588 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 35 | $102,211 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 19 | $82,750 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 35 | $78,431 |
The 10 drugs with the highest cost, of 99 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 99 billing codesPaid by Medicare
$201,171
Medicare patients
133
Services billed
158,836
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| Diabetes | 50% | |
| Arthritis | 42% | |
| Depression | 31% | |
| Chronic kidney disease | 23% | |
| Ischemic heart disease | 19% | |
| Atrial fibrillation | 13% | |
| Heart failure | 11% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, chorionic gonadotropin, per 1,000 usp units J0725 | Office | 19 | 3,462 | $58,436 |
| Injection, testosterone cypionate, 1 mg J1071 | Office | 24 | 124,922 | $2,399 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 47 | 784 | $772 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 12 | 388 | $141 |
| Injection, ondansetron hydrochloride, per 1 mg J2405 | Office | 14 | 452 | $33 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 39 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Biktarvy |
|
$24,224 | 167 | — |
| Descovy |
|
$12,829 | 35 | — |
| Serostim |
|
$6,043 | 22 | — |
| DOVATO |
|
$945 | 35 | — |
| APRETUDE |
|
$564 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 39 with PatronRecords
1,122 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Psychiatric/Mental Health in Illinois
Erin Petrusic
Nurse Practitioner, Psychiatric/Mental Health · Chicago, IL
Melissa Vitale
Nurse Practitioner, Psychiatric/Mental Health · Chicago, IL
Alan Amberg
Nurse Practitioner, Psychiatric/Mental Health · Chicago, IL
Jaime Mendoza
Nurse Practitioner, Psychiatric/Mental Health · Maryville, IL
Jennifer Thery
Nurse Practitioner, Psychiatric/Mental Health · Maryville, IL
Carole Weddington Hunt
Nurse Practitioner, Psychiatric/Mental Health · Granite City, IL
Related records
Nurse Practitioner, Psychiatric/Mental Health in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Psychiatric/Mental Health
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.